Core Insights - Candel Therapeutics, Inc. announced that an abstract was accepted for oral presentation at the AUA 2026 Annual Meeting, focusing on new data from its phase 3 clinical trial of aglatimagene besadenovec in patients with localized prostate cancer [1] Company Overview - Candel is a clinical-stage biopharmaceutical company developing multimodal biological immunotherapies aimed at eliciting systemic anti-tumor immune responses to combat cancer [4] - The company has two clinical-stage platforms based on genetically modified adenovirus and herpes simplex virus (HSV) gene constructs [4] - Aglatimagene besadenovec (CAN-2409) is the lead candidate from the adenovirus platform, having completed successful phase 2a trials in non-small cell lung cancer and pancreatic ductal adenocarcinoma, as well as a pivotal phase 3 trial in localized prostate cancer [4] Clinical Trials and Regulatory Designations - The phase 3 trial of aglatimagene in localized prostate cancer was conducted under a Special Protocol Assessment with the FDA, which granted Fast Track and Regenerative Medicine Advanced Therapy Designations for this treatment [4] - Linoserpaturev (CAN-3110), the lead candidate from the HSV platform, is currently in a phase 1b trial for recurrent high-grade glioma and has received Fast Track and Orphan Drug Designations from the FDA [5] Presentation Details - The presentation at the AUA will be titled "Extended follow-up shows accumulating benefit for patients treated with CAN-2409+prodrug in combination with standard of care external beam radiation in men with localized prostate cancer: update from PrTK03 randomized phase 3 clinical trial" [8] - It is scheduled for May 15, 2026, from 11:30 AM to 11:40 AM ET at the Walter E. Washington Convention Center in Washington, D.C. [8]

Candel Therapeutics Conference Call Summary Company Overview - Candel Therapeutics is focused on developing viral immunotherapies for challenging solid tumors, with two investigational medicines in the clinic: CAN-2409 and CAN-3110 [2][9] Key Points and Arguments CAN-2409 Development - CAN-2409 is a viral immunotherapy designed to immunize patients against their own tumors and distant metastases [2] - Positive data from a pivotal phase III clinical trial in localized prostate cancer was announced in December 2024, achieving primary and secondary endpoints [3] - The trial was conducted under a Special Protocol Assessment (SPA) with the FDA, which confirmed the protocol in writing in 2025 [3] - CAN-2409 received Fast Track designation and Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA, facilitating engagement and process acceleration [4] - Positive data was also reported in therapy-resistant non-small cell lung cancer, with plans for a large pivotal randomized controlled phase III trial to start enrollment imminently [4] CAN-3110 Development - CAN-3110 is a modified herpes simplex virus designed to replicate in tumor cells, leading to immunogenic cell death [6][14] - The therapy has shown a doubling of expected median overall survival in recurrent high-grade glioma patients, with significant biomarker data published in reputable journals [6][20] - CAN-3110 is currently in early-phase clinical trials, with promising outcomes in therapy-resistant conditions [15][17] Financial and Corporate Highlights - Candel Therapeutics is in a stable financial position, having completed structured debt financing and equity deals [7] - The company has paused the pancreatic cancer program to prioritize prostate cancer and non-small cell lung cancer initiatives [5] Clinical Trial Insights - The CAN-2409 trial involved 745 patients, randomized to receive either the treatment or placebo, with a primary endpoint of disease-free survival [29] - The trial demonstrated a statistically significant improvement in disease-free survival, with 80.4% of patients achieving a pathological complete response compared to 63.6% in the placebo group [35] - The treatment was well tolerated, with adverse events comparable to placebo, primarily minor flu-like symptoms [31] Market Opportunity and Strategy - The focus is on increasing the proportion of patients with localized prostate cancer who achieve long-term cancer-free status, addressing a significant unmet need [22][23] - The treatment approach is designed to be patient-friendly, requiring minimal invasive procedures [26] - Payer feedback has been positive, appreciating the clinical data and the one-time treatment cost structure [38] Additional Important Content - The company is preparing for a Biologics License Application (BLA) submission in Q4 of the current year [40] - Future milestones include new data on long-term survival in lung cancer and additional exploratory data from the prostate cancer study [39] - The leadership team has extensive experience in drug discovery and development, supported by a Research Advisory Board comprising notable figures in oncology [21][22] This summary encapsulates the critical aspects of Candel Therapeutics' conference call, highlighting the company's innovative approaches in cancer treatment and its strategic positioning in the market.

Core Insights - Candel Therapeutics, Inc. will host a virtual Research and Development (R&D) Event on December 5, 2025, focusing on its viral immunotherapy approach and oncology pipeline [1][2] Company Overview - Candel Therapeutics is a clinical-stage biopharmaceutical company developing multimodal biological immunotherapies aimed at eliciting systemic anti-tumor immune responses [11][12] - The company has two clinical-stage platforms based on genetically modified adenovirus and HSV gene constructs, with CAN-2409 as the lead candidate from the adenovirus platform [12][13] R&D Event Details - The R&D Day will feature presentations from executive leadership, clinical investigators, and scientific advisors, providing an overview of the company's pipeline [2] - Key presentations will include an introduction by Paul Peter Tak, CEO, and discussions on immuno-oncology innovations [2][3] Product Candidates - CAN-2409 is an investigational, off-the-shelf, replication-defective adenovirus designed to deliver the HSV-tk gene to tumors, showing potential for treating a broad range of solid tumors [9] - More than 1,000 patients have been dosed with CAN-2409 in clinical trials, demonstrating a favorable tolerability profile [9][12] - CAN-3110 is a first-in-class, replication-competent HSV-1 oncolytic viral immunotherapy candidate, currently in a phase 1b clinical trial for recurrent high-grade glioma [10][13] Clinical Trials and Regulatory Designations - Candel has completed successful phase 2a trials for CAN-2409 in non-small cell lung cancer and pancreatic ductal adenocarcinoma, and a pivotal phase 3 trial in localized prostate cancer [12] - The FDA has granted Fast Track and Regenerative Medicine Advanced Therapy Designations to CAN-2409 for various cancer treatments [12]

Core Insights - Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies for cancer treatment [3][4] - The company will present at the Jefferies Global Healthcare Conference on November 18, 2025 [1][2] Company Overview - Candel specializes in off-the-shelf, multimodal viral immunotherapies that aim to elicit individualized, systemic anti-tumor immune responses [3] - The company has two clinical-stage platforms based on genetically modified adenovirus and herpes simplex virus (HSV) [3] Clinical Trials and Designations - Candel has completed successful phase 2a clinical trials for its lead product candidate CAN-2409 in non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC) [4] - CAN-2409 has received Fast Track Designation from the FDA for treating PDAC and stage III/IV NSCLC in specific patient populations [4] - The FDA has also granted Regenerative Medicine Advanced Therapy (RMAT) Designation and Orphan Drug Designation to CAN-2409 for localized prostate cancer and PDAC, respectively [4] Additional Product Candidates - CAN-3110, the lead candidate from the HSV platform, is currently in a phase 1b clinical trial for recurrent high-grade glioma and has received Fast Track and Orphan Drug Designations from the FDA [5] - Candel's enLIGHTEN™ Discovery Platform is designed to create new viral immunotherapies for solid tumors using advanced analytics [5]

Core Insights - Candel Therapeutics has appointed Dr. Bali Pulendran to its Research Advisory Board, enhancing its expertise in systems immunology and vaccinology as it advances its viral immunotherapy candidates [1][2][3] Company Overview - Candel Therapeutics is a clinical-stage biopharmaceutical company focused on developing multimodal viral immunotherapies to elicit systemic anti-tumor immune responses [4] - The company has established two clinical-stage platforms based on genetically modified adenovirus and herpes simplex virus (HSV) gene constructs [4] Product Development - Candel's lead product candidate, CAN-2409, has completed successful phase 2a clinical trials in non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC) [5] - A pivotal phase 3 clinical trial of CAN-2409 in localized prostate cancer is underway, conducted under a Special Protocol Assessment (SPA) with the FDA [5] - CAN-2409 has received Fast Track Designation from the FDA for multiple indications, including PDAC and stage III/IV NSCLC [5] - CAN-3110, the lead candidate from the HSV platform, is currently in a phase 1b clinical trial for recurrent high-grade glioma and has also received Fast Track and Orphan Drug Designations from the FDA [6] Research and Development - Dr. Pulendran's expertise is expected to provide valuable insights into the immune system's response to therapies, aiding in the advancement of CAN-2409 and CAN-3110 [2][3] - Candel's enLIGHTEN™ Discovery Platform leverages human biology and advanced analytics to create new viral immunotherapies for solid tumors [6]

Core Insights - Candel Therapeutics announced promising interim data from its phase 1b clinical trial of CAN-3110 in recurrent glioblastoma, along with a publication in a high-impact journal [1][2] Clinical Trial Findings - The publication details findings from 97 tumor biopsies from two patients, revealing a discordance between immune biomarkers and imaging results, indicating that conventional imaging may misinterpret immune infiltration as disease progression [3][5] - CAN-3110 induced significant changes in the tumor microenvironment, with one patient achieving a complete pathological response [3][4] - The study identified T cell clonotypes targeting CAN-3110 epitopes, supporting the dual mechanism of action of the therapy [4][5] Survival Data - Updated median overall survival (mOS) was reported as 11.8 months for arm A and 12.0 months for arm B, with some patients surviving significantly longer [5][6] - In arm C, 9 patients received multiple administrations of CAN-3110, with a median follow-up of 8.9 months; 4 out of 9 patients were alive at the time of data cutoff [6] Future Directions - The company plans to design a small phase 2 clinical trial for CAN-3110 in recurrent glioblastoma, collaborating with the glioblastoma community and regulators [8] - CAN-3110 has received FDA Fast Track and Orphan Drug Designations, indicating its potential as a treatment for recurrent high-grade glioma [8][11] Company Overview - Candel Therapeutics focuses on developing multimodal biological immunotherapies, with CAN-3110 being a first-in-class oncolytic viral immunotherapy candidate [9][10] - The company has established platforms based on genetically modified adenovirus and herpes simplex virus, with ongoing clinical trials for other product candidates [10][11]